Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intec Pharma

- PMLiVE

Kite files first CAR-T candidate in Europe

But will need to play catch up in the US, where Novartis has a slight lead

AstraZeneca AZ

Shock for AZ as MYSTIC trial stumbles at first hurdle

Combination fails to improve progression-free survival for lung cancer patients

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

- PMLiVE

Merck & Co’s Remicade biosimilar undercuts its US rivals

Its version will be 35% cheaper than J&J's originator product

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Race to CGRP migraine drug finish line enters the final straight

US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab

- PMLiVE

Alcon’s return to growth gives Novartis ‘options’, says CEO

Sales up 3% to $1.5bn in second quarter for ailing eyecare division

- PMLiVE

Alcon’s return to growth gives Novartis ‘options’, says CEO

Sales up 3% to $1.5bn in second quarter for ailing eyecare division

- PMLiVE

Novartis’ CAR-T clears FDA panel with relative ease

Puts tisagenlecleucel-T on course to be first approved personalised CAR-T therapy

- PMLiVE

FDA halts third Merck myeloma trial after patient deaths

More patients died on Keytruda combination than those on other treatments

- PMLiVE

Novartis gets first-line approval for Xalkori challenger in EU

Zykadia showed a 45% reduction in the risk of disease progression compared to chemo

- PMLiVE

CV data sets up Novartis’ Ilaris for blockbuster sales

Drug shown to reduce major adverse cardiovascular events

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links